NCT02907684

Brief Summary

The purpose of this study is to investigate the cardio-metabolic health effects of consuming almond nuts in place of habitual (usual) snack products in adults at moderate risk of developing cardiovascular disease

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 30, 2016

Completed
21 days until next milestone

First Posted

Study publicly available on registry

September 20, 2016

Completed
6 months until next milestone

Study Start

First participant enrolled

March 29, 2017

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 13, 2019

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2019

Completed
Last Updated

December 2, 2019

Status Verified

February 1, 2019

Enrollment Period

2.1 years

First QC Date

August 30, 2016

Last Update Submit

November 29, 2019

Conditions

Keywords

Cardiovascular diseaseNon alcoholic fatty liverDiabetesAlmondsEndothelium-dependent vasodilationFecal short chain fatty acids (SCFAs)Snacking

Outcome Measures

Primary Outcomes (4)

  • Endothelium-dependent vasodilation

    Measured via flow mediated dilation (FMD)

    Baseline (week 2)

  • Endothelium-dependent vasodilation

    Measured via flow mediated dilation (FMD)

    Week 8 (after 2 week run in)

  • Liver fat %

    Via MRI and magnetic resonance spectroscopy (MRS) analysis. Only a subset of 48 participants with aim of 20 per each arm to complete

    Baseline (week 2)

  • Liver fat %

    Via MRI and MRS analysis. Only a subset of 48 participants with aim of 20 per each arm to complete

    Week 8 (after 2 week run in)

Secondary Outcomes (63)

  • Pancreatic fat

    Baseline (week 2)

  • Abdominal fat

    Baseline (week 2)

  • Muscle fat

    Baseline (week 2)

  • Pancreatic fat

    Week 8 (after 2 week run in)

  • Abdominal fat

    Week 8 (after 2 week run in)

  • +58 more secondary outcomes

Other Outcomes (5)

  • Adverse events

    Through study completion, average of 1.5 years.

  • Snack product acceptability

    Week 6

  • 4 day food diaries

    4 days at screening

  • +2 more other outcomes

Study Arms (2)

Almonds

EXPERIMENTAL

Almond snacks

Dietary Supplement: Almonds

Control muffins/crackers

PLACEBO COMPARATOR

Muffin/Cracker snacks

Dietary Supplement: Muffins/Crackers

Interventions

AlmondsDIETARY_SUPPLEMENT

Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks

Almonds
Muffins/CrackersDIETARY_SUPPLEMENT

Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation.

Control muffins/crackers

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects will be male or female, aged between 30-70 years who regularly consume ≥2 snack products a day. A principal aim is to identify and recruit subjects with increased risk of CVD, in order to increase the sensitivity of the study subjects to dietary change. Subjects who are at above average risk for developing CVD (relative risk \>1.5) will be selected using a metabolic scoring system (scoring ≥2 points), adapted from the Framingham risk score system, as used previously by Chong et al. 2012. Subjects will give their own written informed consent.

You may not qualify if:

  • Non-snack consumers (assessed as subjects consuming \<2 snack products per day by a specific FFQ (food frequency questionnaire) at screening, adapted from the short Health Survey for England (2007) Eating Habits Questionnaire).
  • A reported history of myocardial infarction or cancer.
  • Being fitted with a heart pacemaker.
  • Presence of metal inside the body (implants, devices, shrapnel, metal particles in eyes from welding etc.). History of black-outs/epilepsy.
  • Diabetes mellitus (fasting plasma glucose \>7 mmol/L).
  • Chronic coronary, renal or bowel disease or history of cholestatic liver disease or pancreatitis.
  • Presence of gastrointestinal disorder or use of a drug, which is likely to alter gastrointestinal motility or nutrient absorption.
  • History of substance abuse or alcoholism (past history of alcohol intake \>60 units/men or 50 units/women).
  • Currently pregnant, planning pregnancy, breastfeeding or having had a baby in the last 12 months.
  • Allergy or intolerance to nuts.
  • Unwilling to follow the protocol and/or give informed consent.
  • Weight change of \> 3 kg in preceding 2 months. BMI \<18 kg/m2 (underweight) or \>40 kg/m2 (morbidly obese due to potential technical difficulties making FMD and ambulatory blood pressure (ABP) measurements).
  • Current smokers or individuals who quit smoking within the last 6 months.
  • Participation in other research trials involving dietary or drug intervention and/ or blood collection in the past 3 months.
  • Unable or unwilling to comply with study protocol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King's College London, Diabetes and Nutritional Sciences Division

London, SE1 9NH, United Kingdom

Location

Related Publications (1)

  • Dikariyanto V, Smith L, Francis L, Robertson M, Kusaslan E, O'Callaghan-Latham M, Palanche C, D'Annibale M, Christodoulou D, Basty N, Whitcher B, Shuaib H, Charles-Edwards G, Chowienczyk PJ, Ellis PR, Berry SEE, Hall WL. Snacking on whole almonds for 6 weeks improves endothelial function and lowers LDL cholesterol but does not affect liver fat and other cardiometabolic risk factors in healthy adults: the ATTIS study, a randomized controlled trial. Am J Clin Nutr. 2020 Jun 1;111(6):1178-1189. doi: 10.1093/ajcn/nqaa100.

MeSH Terms

Conditions

Cardiovascular DiseasesNon-alcoholic Fatty Liver DiseaseDiabetes Mellitus

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Sarah Berry, PhD

    King's College London

    PRINCIPAL INVESTIGATOR
  • Wendy Hall, PhD

    King's College London

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 30, 2016

First Posted

September 20, 2016

Study Start

March 29, 2017

Primary Completion

May 13, 2019

Study Completion

October 30, 2019

Last Updated

December 2, 2019

Record last verified: 2019-02

Data Sharing

IPD Sharing
Will not share

Locations